COMPREHENSIVE HIV/AIDS ANTIRETROVIRAL (ART) PRODUCT LIST
The list below has been expanded to include most antiretroviral molecules and combinations currently used in the Indian HIV market, including NACO first-line, second-line, pediatric, salvage therapy, and private-market products. Current Indian HIV treatment is heavily centered on Dolutegravir (DTG), Tenofovir (TDF/TAF), Lamivudine (3TC), Abacavir (ABC), Darunavir (DRV), Atazanavir (ATV), Ritonavir (RTV), and Raltegravir (RAL).
Leading the Future of HIV/AIDS Treatment with Advanced Antiretroviral Medicines
The global healthcare community has made remarkable progress in the management of Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) through the widespread availability of effective Antiretroviral Therapy (ART). Modern ART regimens have transformed HIV infection from a life-threatening condition into a manageable chronic disease, enabling millions of people worldwide to live longer, healthier, and more productive lives.
At Taj Pharma, we are dedicated to supporting governments, healthcare institutions, international procurement agencies, NGOs, hospitals, distributors, and pharmaceutical partners with a comprehensive portfolio of more than 45 HIV/ART products covering first-line, second-line, pediatric, and advanced treatment regimens. Our antiretroviral portfolio aligns with international treatment standards and includes a broad range of NRTIs, NNRTIs, Protease Inhibitors, Integrase Inhibitors, fixed-dose combinations, pediatric formulations, and next-generation HIV therapies.
NRTI (Nucleoside/Nucleotide Reverse Transcriptase Inhibitors)
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Abacavir | ABATAJ | Antiretroviral (NRTI) | Tablet | 300 mg | Class III |
| Lamivudine | LAMITAJ | Antiretroviral (NRTI) | Tablet | 150 mg, 300 mg | Class III |
| Lamivudine | LAMITAJ Syrup | Antiretroviral (NRTI) | Syrup | 50 mg/5 ml | Class III |
| Zidovudine | ZIDOTAJ | Antiretroviral (NRTI) | Tablet | 300 mg | Class I |
| Zidovudine | ZIDOTAJ Syrup | Antiretroviral (NRTI) | Syrup | 50 mg/5 ml | Class I |
| Tenofovir Disoproxil Fumarate | TENOTAJ | Antiretroviral (NRTI) | Tablet | 300 mg | Class III |
| Tenofovir Alafenamide | TAFTAJ | Antiretroviral (NRTI) | Tablet | 25 mg | Class II |
| Emtricitabine | EMTRITAJ | Antiretroviral (NRTI) | Capsule/Tablet | 200 mg | Class I |
NNRTI (Non-Nucleoside Reverse Transcriptase Inhibitors)
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Nevirapine | NEVITAJ | Antiretroviral (NNRTI) | Tablet | 200 mg | Class II |
| Nevirapine | NEVITAJ Suspension | Oral Suspension | 10 mg/ml | Class II | |
| Efavirenz | EFAVITAJ | Antiretroviral (NNRTI) | Tablet | 400 mg, 600 mg | Class II |
| Etravirine | ETRATAJ | Antiretroviral (NNRTI) | Tablet | 100 mg, 200 mg | Class II |
| Rilpivirine | RILPITAJ | Antiretroviral (NNRTI) | Tablet | 25 mg | Class II |
| Doravirine | DORATAJ | Antiretroviral (NNRTI) | Tablet | 100 mg | Class II |
Comprehensive HIV/AIDS Treatment Solutions
The management of HIV infection requires carefully selected combinations of antiretroviral medicines that suppress viral replication, strengthen immune function, reduce opportunistic infections, and support long-term treatment success.
Our HIV portfolio has been designed to address the diverse therapeutic needs of healthcare systems worldwide, ensuring access to high-quality medicines across all stages of HIV treatment.
The Taj Pharma HIV portfolio includes:
- Adult HIV treatment formulations
- Pediatric HIV formulations
- First-line ART regimens
- Second-line ART regimens
- Salvage therapy products
- Fixed-dose combinations (FDCs)
- Single-agent antiretroviral medicines
- Advanced integrase inhibitor-based therapies
- Modern tenofovir alafenamide-based regimens
Protease Inhibitors (PI)
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Ritonavir | RITOTAJ | Protease Inhibitor Booster | Tablet | 100 mg | Class IV |
| Atazanavir | ATAZATAJ | Protease Inhibitor | Capsule | 150 mg, 300 mg | Class II |
| Lopinavir + Ritonavir | LOPIRITAJ | Protease Inhibitor Combination | Tablet | 200 mg + 50 mg | Class IV |
| Darunavir | DARUTAJ | Protease Inhibitor | Tablet | 400 mg, 600 mg, 800 mg | Class IV |
| Darunavir + Ritonavir | DARURITAJ | Protease Inhibitor Combination | Tablet | 400/50 mg, 600/100 mg, 800/100 mg | Class IV |
| Atazanavir + Ritonavir | ATAZRITAJ | Protease Inhibitor Combination | Tablet | 300 mg + 100 mg | Class II |
Integrase Strand Transfer Inhibitors (INSTI)
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class (Estimate) |
|---|---|---|---|---|---|
| Dolutegravir | DOLUTAJ | Integrase Inhibitor | Tablet | 50 mg | Class II |
| Dolutegravir Pediatric | DOLUTAJ Junior | Integrase Inhibitor | Tablet | 10 mg | Class II |
| Raltegravir | RALTEGTAJ | Integrase Inhibitor | Tablet | 400 mg | Class II |
| Raltegravir | RALTEGTAJ Chew | Chewable Tablet | 100 mg | Class II | |
| Elvitegravir | ELVITAJ | Integrase Inhibitor | Tablet | 150 mg | Class II |
| Bictegravir | BICTAJ | Integrase Inhibitor | Tablet | 50 mg | Class II |
DUAL COMBINATIONS
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class |
|---|---|---|---|---|---|
| Lamivudine + Zidovudine | LAMIZIDTAJ | NRTI Combination | Tablet | 150 mg + 300 mg | III |
| Lamivudine + Zidovudine DT | LAMIZIDTAJ DT | Pediatric FDC | Dispersible Tablet | 30 mg + 60 mg | III |
| Abacavir + Lamivudine | ABALAMTAJ | NRTI Combination | Tablet | 120/60 mg, 600/300 mg | III |
| Tenofovir + Lamivudine | TENLAMTAJ | NRTI Combination | Tablet | 300 mg + 300 mg | III |
| Tenofovir + Emtricitabine | TENEMTAJ | NRTI Combination | Tablet | 300 mg + 200 mg | III |
| Tenofovir Alafenamide + Emtricitabine | TAFEMTAJ | NRTI Combination | Tablet | 25 mg + 200 mg | II |
| Dolutegravir + Lamivudine | DOLLAMTAJ | Dual Therapy | Tablet | 50 mg + 300 mg | II |
TRIPLE COMBINATIONS (FIRST-LINE & MODERN ART)
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class |
|---|---|---|---|---|---|
| Tenofovir + Lamivudine + Dolutegravir (TLD) | TLDTAJ | First-Line ART | Tablet | 300 + 300 + 50 mg | II |
| Tenofovir + Emtricitabine + Dolutegravir | TENEMDOLTAJ | Triple ART | Tablet | 300 + 200 + 50 mg | II |
| Tenofovir Alafenamide + Emtricitabine + Dolutegravir | TAFEMDOLTAJ | Advanced Triple ART | Tablet | 25 + 200 + 50 mg | II |
| Lamivudine + Tenofovir + Efavirenz | LAMTENEFTAJ | Triple ART | Tablet | 300 + 300 + 400 mg | II |
| Lamivudine + Tenofovir + Efavirenz | LAMTENEFTAJ Forte | Triple ART | Tablet | 300 + 300 + 600 mg | II |
| Abacavir + Lamivudine + Dolutegravir | ABALAMDOLTAJ | Triple ART | Tablet | 600 + 300 + 50 mg | III |
| Abacavir + Lamivudine + Dolutegravir Pediatric | ABALAMDOLTAJ DT | Pediatric Triple ART | Dispersible Tablet | 60 + 30 + 5 mg | III |
| Zidovudine + Lamivudine + Nevirapine | ZLAMNEVTAJ | Triple ART | Tablet | 300 + 150 + 200 mg | III |
| Zidovudine + Lamivudine + Efavirenz | ZLAMEFTAJ | Triple ART | Tablet | 300 + 150 + 600 mg | III |
SECOND-LINE & SALVAGE REGIMEN PRODUCTS
Widely used in India for treatment-experienced or resistant HIV patients.
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths | BCS Class |
|---|---|---|---|---|---|
| Atazanavir + Ritonavir | ATAZRITAJ | Second-Line ART | Tablet | 300 + 100 mg | II |
| Darunavir + Ritonavir | DARURITAJ | Second-Line ART | Tablet | 600 + 100 mg | IV |
| Darunavir + Ritonavir + Dolutegravir | DARUDOLTAJ | Salvage Therapy | Tablet Kit | 600 + 100 + 50 mg | IV |
| Lopinavir/Ritonavir + Dolutegravir | LOPIDOLTAJ | Salvage Therapy | Tablet Kit | Various | IV |
| Tenofovir + Lamivudine + Atazanavir/Ritonavir | TENLAMATAJ-R | Second-Line ART Kit | Kit | Various | III |
| Zidovudine + Lamivudine + Atazanavir/Ritonavir | ZLAMATAJ-R | Second-Line ART Kit | Kit | Various | III |
NEWER PRIVATE-MARKET HIV PRODUCTS
Available primarily in private HIV care and specialty markets.
| Product Name | Brand Name | Therapeutic Category | Dosage Form | Available Strengths |
|---|---|---|---|---|
| Bictegravir + Emtricitabine + Tenofovir Alafenamide | BICTEMTAFTAJ | Single Tablet Regimen | Tablet | 50 + 200 + 25 mg |
| Dolutegravir + Rilpivirine | DOLRILTAJ | Two Drug Regimen | Tablet | 50 + 25 mg |
| Doravirine + Lamivudine + Tenofovir | DORLAMTENTAJ | Triple ART | Tablet | 100 + 300 + 300 mg |
NRTI Antiretroviral Medicines: Foundation of HIV Treatment
Abacavir (ABATAJ)
Abacavir remains one of the most important nucleoside reverse transcriptase inhibitors used in HIV treatment. It is commonly utilized in both adult and pediatric antiretroviral regimens and serves as a critical component of numerous combination therapies.
Available Strengths
- Abacavir 300 mg Tablets
Key Applications
- First-line HIV treatment
- Pediatric HIV regimens
- Fixed-dose combinations
- Alternative backbone therapy
Lamivudine (LAMITAJ)
Lamivudine is one of the most widely prescribed HIV medicines globally. Its established efficacy and excellent tolerability make it a cornerstone component of numerous antiretroviral combinations.
Available Formulations
- Lamivudine 150 mg Tablets
- Lamivudine 300 mg Tablets
- Lamivudine Oral Syrup
Benefits
- High treatment acceptance
- Strong clinical experience
- Broad inclusion in ART guidelines
Tenofovir Disoproxil Fumarate (TENOTAJ)
Tenofovir DF remains a critical first-line HIV medicine used in millions of treatment regimens worldwide.
Advantages
- Potent antiviral activity
- Once-daily dosing compatibility
- Extensive clinical evidence
- Preferred backbone therapy
Tenofovir Alafenamide (TAFTAJ)
Tenofovir Alafenamide represents a modern advancement in HIV treatment and has become an increasingly important component of contemporary antiretroviral therapy.
Clinical Advantages
- Advanced formulation technology
- Strong antiviral efficacy
- Suitable for modern treatment protocols
Emtricitabine (EMTRITAJ)
Emtricitabine is frequently combined with tenofovir-based therapies and plays a central role in modern HIV treatment programs.
Benefits
- Excellent compatibility with fixed-dose combinations
- Strong antiviral profile
- Broad global acceptance
NNRTI-Based HIV Medicines
Nevirapine (NEVITAJ)
Nevirapine has maintained an important role in HIV treatment, particularly within pediatric treatment programs and established ART protocols.
Available Formulations
- Nevirapine 200 mg Tablets
- Nevirapine Oral Suspension
Efavirenz (EFAVITAJ)
Efavirenz has long been recognized as one of the most widely used NNRTIs in HIV treatment history.
Available Strengths
- 400 mg Tablets
- 600 mg Tablets
Clinical Applications
- First-line treatment regimens
- Fixed-dose combinations
- Global ART programs
Etravirine, Rilpivirine and Doravirine
Modern NNRTIs continue to expand treatment options for HIV-positive patients requiring individualized therapy.
Portfolio Coverage
- ETRATAJ (Etravirine)
- RILPITAJ (Rilpivirine)
- DORATAJ (Doravirine)
These medicines provide additional flexibility for healthcare professionals managing treatment-experienced patients and specialized HIV populations.
Integrase Inhibitors: Modern Standard of HIV Care
Integrase inhibitors have become the preferred choice in many HIV treatment guidelines due to their potency, safety profile, and rapid viral suppression.
Dolutegravir (DOLUTAJ)
Dolutegravir is widely recognized as one of the most effective antiretroviral medicines available today.
Available Strengths
- Dolutegravir 50 mg Tablets
- Dolutegravir 10 mg Pediatric Tablets
Advantages
- High genetic barrier to resistance
- Rapid viral suppression
- Once-daily treatment compatibility
- Preferred first-line therapy component
Raltegravir (RALTEGTAJ)
Raltegravir remains a highly effective integrase inhibitor suitable for both adult and pediatric HIV treatment.
Available Formulations
- Raltegravir 400 mg Tablets
- Raltegravir 100 mg Chewable Tablets
Benefits
- Proven efficacy
- Pediatric suitability
- Flexible treatment options
Elvitegravir and Bictegravir
The newest generation of integrase inhibitors continues to improve treatment outcomes and simplify HIV management.
Available Products
- ELVITAJ (Elvitegravir)
- BICTAJ (Bictegravir)
These molecules represent advanced options within modern HIV treatment strategies.
Protease Inhibitors for Second-Line and Advanced HIV Treatment
Protease inhibitors remain essential in the management of treatment-experienced patients and second-line HIV therapy.
Atazanavir (ATAZATAJ)
Atazanavir is widely utilized as part of boosted protease inhibitor regimens.
Available Strengths
- 150 mg Capsules
- 300 mg Capsules
Clinical Benefits
- Strong antiviral activity
- Proven long-term effectiveness
- Widely used in second-line ART
Lopinavir + Ritonavir (LOPIRITAJ)
This established combination remains a trusted option in HIV treatment programs worldwide.
Available Strength
- 200 mg + 50 mg Tablets
Darunavir (DARUTAJ) and Darunavir + Ritonavir (DARURITAJ)
Darunavir-based therapy plays a critical role in managing resistant HIV infections and treatment-experienced patients.
Available Strengths
- Darunavir 400 mg
- Darunavir 600 mg
- Darunavir 800 mg
- Darunavir/Ritonavir combinations
Benefits
- High resistance barrier
- Effective salvage therapy option
- Preferred second-line regimen component
Fixed-Dose Combination HIV Medicines
Fixed-dose combinations improve adherence by reducing pill burden and simplifying treatment schedules.
TENLAMTAJ
Tenofovir + Lamivudine
A widely used dual NRTI backbone combination.
TENEMTAJ
Tenofovir + Emtricitabine
One of the most recognized HIV treatment combinations worldwide.
ABALAMTAJ
Abacavir + Lamivudine
Available in pediatric and adult strengths for broad treatment coverage.
DOLLAMTAJ
Dolutegravir + Lamivudine
A modern dual-drug therapy option supporting simplified HIV management.
Triple Antiretroviral Therapy Products
TLDTAJ
Tenofovir + Lamivudine + Dolutegravir
The preferred first-line ART regimen in many national HIV treatment programs.
Advantages
- Simplified once-daily therapy
- Excellent treatment outcomes
- High patient adherence
TENEMDOLTAJ
Tenofovir + Emtricitabine + Dolutegravir
An advanced triple-drug regimen combining potent antiviral activity with treatment convenience.
TAFEMDOLTAJ
Tenofovir Alafenamide + Emtricitabine + Dolutegravir
A modern HIV treatment option designed to meet evolving clinical requirements.
LAMTENEFTAJ
Lamivudine + Tenofovir + Efavirenz
A globally established triple-combination ART regimen.
ABALAMDOLTAJ
Abacavir + Lamivudine + Dolutegravir
Available in adult and pediatric formulations, supporting comprehensive HIV treatment across age groups.
Pediatric HIV Treatment Portfolio
Children living with HIV require specialized formulations designed for accurate dosing and improved adherence.
Taj Pharma offers an extensive pediatric HIV portfolio including:
- Nevirapine Oral Suspension
- Lamivudine Oral Syrup
- Zidovudine Oral Syrup
- Dolutegravir Pediatric Tablets
- Raltegravir Chewable Tablets
- Lamivudine + Zidovudine Dispersible Tablets
- Abacavir + Lamivudine + Dolutegravir Dispersible Tablets
These formulations help support treatment continuity from infancy through adolescence.
WHO and NACO-Aligned HIV Treatment Coverage
Our HIV product portfolio supports treatment strategies aligned with internationally recognized HIV management practices and national treatment programs.
Coverage includes:
- First-line HIV treatment regimens
- Second-line HIV treatment regimens
- Integrase inhibitor-based therapies
- Protease inhibitor-based regimens
- Pediatric HIV treatment protocols
- Treatment-experienced patient management
- Advanced salvage therapy solutions
This comprehensive approach enables healthcare providers to manage HIV effectively across a wide range of clinical scenarios.
Global Manufacturing Excellence at Taj Pharma
Quality, safety, and reliability remain central to every HIV medicine manufactured by Taj Pharma.
Our manufacturing operations support:
- WHO-GMP Standards
- International Quality Systems
- Regulatory Documentation Support
- Government Tender Participation
- Ministry of Health Procurement Programs
- NGO Supply Programs
- International HIV Treatment Initiatives
- Global Pharmaceutical Distribution Networks
Through rigorous quality assurance and continuous innovation, we remain committed to expanding access to affordable, high-quality HIV medicines worldwide.
With more than 45 HIV/ART products, Taj Pharma offers one of the most comprehensive antiretroviral portfolios available for global healthcare markets. Covering NRTIs, NNRTIs, Protease Inhibitors, Integrase Inhibitors, pediatric formulations, fixed-dose combinations, first-line regimens, second-line therapies, and advanced HIV treatment solutions, our portfolio supports the evolving needs of healthcare providers, procurement agencies, and HIV treatment programs across the world. Through quality-driven manufacturing and a commitment to global health, we continue to strengthen access to life-saving antiretroviral therapy for patients living with HIV/AIDS.







